A2 Refereed review article in a scientific journal
Current challenges in applying gene-driven therapies in clinical lung cancer practice
Authors: Saarenheimo Jatta, Andersen Heidi, Eigeliene Natalja, Jekunen Antti P.
Publisher: BAISHIDENG PUBLISHING GROUP INC
Publication year: 2021
Journal: World Journal of Clinical Oncology
Journal name in source: WORLD JOURNAL OF CLINICAL ONCOLOGY
Journal acronym: WORLD J CLIN ONCOL
Volume: 12
Issue: 8
First page : 656
Last page: 663
Number of pages: 8
ISSN: 2218-4333
DOI: https://doi.org/10.5306/wjco.v12.i8.656(external)
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/67223188(external)
Over the last twenty years, with the development of gene-driven therapies, numerous new drugs have entered clinical use. Very few of these new drugs are suitable for a large number of patients, and all require molecular genetic testing. In lung cancer, gene-targeted therapy has evolved rapidly and has placed demands on the development of diagnostics and tissue sample preparation and logistics. Rapid diagnosis and prevalence assessment are necessary to determine the prognosis of a lung cancer patient based on the latest research findings. Therefore, the molecular-genetic diagnostic pathway must also be accelerated and matured to do the necessary analyses on small samples. Because lung cancer rebiopsy can be difficult, liquid biopsy techniques should be developed to cover more of the treatable mutations. There are obstacles related to tissue sampling, new genomic techniques and access to gene-driven cancer drugs, including their affordability. With this review and case study, we go into the obstacles faced by our clinic and discuss how to tackle these obstacles in lung cancer. We use lung cancer as an example due to its complexity, though these same obstacles are found in different cancers on a minor scale.
Downloadable publication This is an electronic reprint of the original article. |  |
